DCTH Delcath Systems, Inc.
USHealthcareAs of 2026-07-10 16:00
Why DCTH matters now
Delcath Systems, Inc. (DCTH) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.01 with -3.77% on the session and $449.1M in market capitalization; recent performance reads 1-month +7.74% and YTD +15.74%.
The latest financial table shown here is Q1 2026, with revenue of $25.0M, net income of $-1.1M, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E 129.20 and FCF yield 4.8%.
The latest indexable market news headline is "Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $23.00; recent insider activity includes Aharon Gil filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
129.20
PEG
1.17
P/B
3.74
P/S
4.46
EV/EBITDA
217.72
DCF Value
$-149.90
FCF Yield
4.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.0%
Operating Margin
-1.8%
Net Margin
0.6%
ROE
0.5%
ROA
0.4%
ROIC
-0.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $25.0M | $-1.1M | $-0.03 |
| Q4 2025 | $20.7M | $-1.9M | $-0.05 |
| FY 2025 | $85.2M | $2.7M | $0.07 |
| Q3 2025 | $20.6M | $830.0K | $0.02 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$23.00
Target (Median)
$23.00
Target Range
$19.00 - $27.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.52
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.